Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)
Close on Nov 17, 2026Market cap $13.19MP/E –Yield –
Earnings
Lipocine's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$2.30M
+1907.4% on a year earlier
EPS, Q3 FY2026
-$0.08
-$0.59 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Lipocine's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 9, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026during market hours | $2.30M | +1907.4% | -$0.08 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026before the open | $190.00K | -69.5% | -$0.32 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | -$0.52 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 10, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $114.57K | – | -$0.59 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $622.85K | – | -$0.41 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024before the open | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Jan 25, 2021after the close | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 8, 2017before the open | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 7, 2017before the open | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 8, 2017before the open | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Mar 6, 2017after the close | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Nov 8, 2016before the open | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 9, 2016before the open | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 9, 2016after the close | – | – | – | Filing |
| Q4 FY2015ended Dec 31, 2015 | Mar 10, 2016after the close | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Nov 12, 2015after the close | – | – | – | Filing |
| Q2 FY2015ended Jun 30, 2015 | Aug 11, 2015before the open | – | – | – | Filing |
| Q1 FY2015ended Mar 31, 2015 | May 7, 2015before the open | – | – | – | Filing |
| Q4 FY2014ended Dec 31, 2014 | Mar 11, 2015before the open | – | – | – | Filing |
| Q3 FY2014ended Sep 30, 2014 | Nov 10, 2014before the open | – | – | – | Filing |
| Q2 FY2014ended Jun 30, 2014 | Aug 13, 2014after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Lipocine has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Lipocine puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Lipocine filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- News
- News
- Results
- Update
- News
- News
- News
- News
- News
- News
See a number that looks wrong?